Curis Inc Dossier - Source-backed chat

Curis Inc

CRISNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.83Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2M

Enterprise Value −$11.6M

Shares Outstanding 2.4M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Curis Inc. is a clinical-stage biotechnology company highly focused on the development of its lead drug candidate, emavusertib (CA-4948), an orally available small molecule IRAK4 and FLT3 inhibitor. The company's primary value driver is its clinical pipeline targeting hematologic malignancies, specifically primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL). Despite historical cash constraints, a strategic PIPE financing in early 2026 has extended its cash runway into the second half of 2027, aligning with critical clinical readouts. Wall Street maintains a highly bullish outlook on the stock due to the significant therapeutic potential of emavusertib's dual-pathway inhibition mechanism.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$42.67

High · most bullish analyst$65.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case involves clinical delays in the TakeAim CLL study or safety concerns (such as dose-limiting toxicities) that prevent the successful dosing of the 5th patient. This would block the exercise of the Series B warrants, leaving the company with a severe cash shortfall by early 2027 and forcing highly dilutive equity raises or a halt in clinical programs.

Base CaseCentral scenario

The base case assumes Curis successfully completes the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, triggering up to $20.2 million in additional cash from Series B warrant exercises. This capital secures operations into late 2027, allowing the company to report initial CLL data in December 2026 and advance its registrational TakeAim Lymphoma study in PCNSL toward accelerated approval filings.

Bull CaseUpside scenario

Curis's bull case is driven by the clinical development and therapeutic potential of its pipeline, specifically its lead drug candidate emavusertib (an IRAK4 and FLT3 inhibitor) in the TakeAim Lymphoma and TakeAim CLL studies. The combination of emavusertib with BTK inhibitors enables a dual blockade of the NF-kB pathway (by targeting both the BCR and TLR pathways), which could significantly improve efficacy in treating complex hematologic malignancies. Additionally, the company holds exclusive GLI inhibitor intellectual property covering five patent families extending to 2029, positioning it uniquely in the Hedgehog pathway inhibitor market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Innovative dual-mechanism of action targeting IRAK4 and FLT3 mutations critical in leukemogenesis.
Strong preliminary efficacy signals, including a 100% objective response rate (ORR) in BTKi-naïve PCNSL patients.
Strategic PIPE financing structure that aligns capital inflows directly with clinical execution milestones.
Orphan Drug Designations from both the FDA and European Commission for PCNSL, AML, and MDS.

Key Investment Risks

Going concern risk and high cash burn rate typical of clinical-stage biotechnology companies.
Heavy dependence on a single primary asset, emavusertib, making any clinical or regulatory delay highly damaging.
Risk of clinical trial enrollment delays, particularly in rare indications like PCNSL.

Thesis Invalidation Triggers

Failure to dose the 5th patient in the TakeAim CLL study, which would prevent the critical Series B warrant funding.
Severe adverse safety events or dose-limiting toxicities emerging in the emavusertib combination trials.
Inability to meet Nasdaq minimum bid price requirements leading to potential delisting.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.